316 related articles for article (PubMed ID: 14985437)
21. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis.
Holbert S; Denghien I; Kiechle T; Rosenblatt A; Wellington C; Hayden MR; Margolis RL; Ross CA; Dausset J; Ferrante RJ; Néri C
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1811-6. PubMed ID: 11172033
[TBL] [Abstract][Full Text] [Related]
22. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
[TBL] [Abstract][Full Text] [Related]
23. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity.
Kaytor MD; Wilkinson KD; Warren ST
J Neurochem; 2004 May; 89(4):962-73. PubMed ID: 15140195
[TBL] [Abstract][Full Text] [Related]
24. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis.
Li SH; Lam S; Cheng AL; Li XJ
Hum Mol Genet; 2000 Nov; 9(19):2859-67. PubMed ID: 11092762
[TBL] [Abstract][Full Text] [Related]
25. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
26. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.
Kahlem P; Green H; Djian P
Mol Cell; 1998 Mar; 1(4):595-601. PubMed ID: 9660943
[TBL] [Abstract][Full Text] [Related]
28. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.
Kim M; Lee HS; LaForet G; McIntyre C; Martin EJ; Chang P; Kim TW; Williams M; Reddy PH; Tagle D; Boyce FM; Won L; Heller A; Aronin N; DiFiglia M
J Neurosci; 1999 Feb; 19(3):964-73. PubMed ID: 9920660
[TBL] [Abstract][Full Text] [Related]
29. Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin.
Ruan Q; Quintanilla RA; Johnson GV
J Neurochem; 2007 Jul; 102(1):25-36. PubMed ID: 17403029
[TBL] [Abstract][Full Text] [Related]
30. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.
Sieradzan KA; Mechan AO; Jones L; Wanker EE; Nukina N; Mann DM
Exp Neurol; 1999 Mar; 156(1):92-9. PubMed ID: 10192780
[TBL] [Abstract][Full Text] [Related]
31. Mutant huntingtin aggregates do not sensitize cells to apoptotic stressors.
Chun W; Lesort M; Lee M; Johnson GV
FEBS Lett; 2002 Mar; 515(1-3):61-5. PubMed ID: 11943195
[TBL] [Abstract][Full Text] [Related]
32. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.
Mende-Mueller LM; Toneff T; Hwang SR; Chesselet MF; Hook VY
J Neurosci; 2001 Mar; 21(6):1830-7. PubMed ID: 11245667
[TBL] [Abstract][Full Text] [Related]
33. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
Wang H; Lim PJ; Karbowski M; Monteiro MJ
Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
[TBL] [Abstract][Full Text] [Related]
34. Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases.
Furukawa Y; Kaneko K; Matsumoto G; Kurosawa M; Nukina N
J Neurosci; 2009 Apr; 29(16):5153-62. PubMed ID: 19386911
[TBL] [Abstract][Full Text] [Related]
35. The selective vulnerability of nerve cells in Huntington's disease.
Sieradzan KA; Mann DM
Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
[TBL] [Abstract][Full Text] [Related]
36. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
Lunkes A; Mandel JL
Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
[TBL] [Abstract][Full Text] [Related]
37. Nuclear targeting of mutant Huntingtin increases toxicity.
Peters MF; Nucifora FC; Kushi J; Seaman HC; Cooper JK; Herring WJ; Dawson VL; Dawson TM; Ross CA
Mol Cell Neurosci; 1999 Aug; 14(2):121-8. PubMed ID: 10479410
[TBL] [Abstract][Full Text] [Related]
38. ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.
Liang Y; Jiang H; Ratovitski T; Jie C; Nakamura M; Hirschhorn RR; Wang X; Smith WW; Hai T; Poirier MA; Ross CA
Brain Res; 2009 Aug; 1286():221-9. PubMed ID: 19559011
[TBL] [Abstract][Full Text] [Related]
39. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
Kim YJ; Yi Y; Sapp E; Wang Y; Cuiffo B; Kegel KB; Qin ZH; Aronin N; DiFiglia M
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12784-9. PubMed ID: 11675509
[TBL] [Abstract][Full Text] [Related]
40. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease.
Miki Y; Tanji K; Mori F; Wakabayashi K
Neurobiol Dis; 2015 Feb; 74():25-31. PubMed ID: 25449906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
